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refractory follicular lymphoma, diffuse large B cell lym-
phoma and lymphoplasmacytic lymphoma and upfront
consolidation for mantle cell lymphoma. 8 (36.4%) pts
underwent AutoSCT as consolidative therapy and 14
(63.6%) pts for relapsed/refractory disease. Therapies prior
to AutoSCT were 1-3 regimens. Time to engraftment was
11.71.79 days for neutrophils and 15.322.6 days for
platelets. Be-EAM-related toxicities included nausea,
emesis, diarrhea, neutropenic fever and mucositis. 13
(59%) pts had severe mucositis (Grade 3/4) with 5 pts
developing neutropenic enterocolitis including 1 patient
with pneumatosis intestinalis. Overall, 18 (81.8%) pts were
in CR and 2 (9%) pts had minimal disease at D100. 5
(22.7%) pts had relapsed disease. 4 (18.2%) pts died from
relapsed or progressive disease.
Conclusion: Bendamustine based conditioning is an effec-
tive regimen in patients with NHL undergoing autologous
stem cell transplantation as previously reported. It has the
potential of causing severe mucositis irrespective of age,
comorbidities, disease type or number of prior therapies.
This regimen although moderately tolerated should be used
cautiously especially in patients who have had prior thera-
pies that can affect the gastrointestinal tract.166
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Introduction: We have previously shown that as
compared with chemo-mobilization (CHM) cytokine
mobilization (CTM) is associated with a better chance ofTable 1
Primary Endpoint Analysis
Chemo-
mobilization
(N[19)
Cytokine
mobilization
(N[55)
p-value
Median total CD34 cells/kg
collected (in millions/kg):
Myeloma 14.9 8.37 0.01
Non-myeloma 4.47 5.03 0.71
Median number of apheresis
days (mean):
Myeloma 1 (1.75) 1 (1.76) 0.99
Non-myeloma 2 (1.67) 1 (1.59) 0.89
Target dose achieved: 0.05
Yes 16 (84.2%) 51 (92.7%)
No 3 (15.8%) 4 (7.3%)
Median day 1 CD34 collection
(in millions/kg):
0.01
Myeloma NA 6.86
Non-myeloma NA 3.67achieving a target autologous stem cell dose for patients
with multiple myeloma (MM). We now review our expe-
rience of autologous stem cell mobilization using a similar
strategy for all patients referred for an autologous trans-
plant (auto-SCT).
Methods: We analyzed consecutive patients who received
an auto-SCT for hematological malignancies at our center
from July 2010 to June 2013. CHM was achieved with
cyclophosphamide (4 g/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose
collected or maximum of 4 days apheresis). CTM was
achieved with pegﬁlgrastim and plerixafor. We recorded
the total CD34+ cells/kg collection, number of apheresis
days, and if the prescribed dose of CD34+ cells/kg was
achieved. The prescribed cell dose in patients with MM is
6.0 x 106/kg, and 3.0 x 106/kg for all other hematological
malignancies. We compared the median total CD34+ cells/
kg dose collection (Wilcoxon test), the mean number of
apheresis days (Poission), and target stem cell dose
collection (non-inferiority test on two proportions). We
also compared day 1 stem cell collection in the CTM
group based on disease (myeloma vs. non-myeloma)
(Wilcoxon test). Finally, we analyzed the probability of
successful stem cell dose collection if the target collection
dose was higher than our own criteria.
Results: A total of 74 patients were included. Fifty-three
patients had a diagnosis of MM and twenty-one patients had
other hematological malignancies, non-Hodgkin (n¼15) and
Hodgkin lymphoma (n¼2). There was no statistically signif-
icant difference in age, gender, number of prior induction
treatment, prior treatment with lenalidomide and time from
diagnosis to transplant between the two groups. In the CHM
group, 7 (47%) were hospitalized from complications of
mobilization regimen, whereas no patients were hospital-
ized in the CTM group (p<0.001). There was no statistically
signiﬁcant difference in neutrophil or platelet engraftment
between CHM and CTM. Multivariate analysis did not reveal
predictive factors which lead to>1 apheresis attempts. Table
1 describes the primary outcomes.
Conclusion: Cytokine-mobilization with pegﬁlgrastim and
planned plerixafor is an effective strategy for stem cell mobi-
lization in patients being considered for autologous transplant.
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Background: Serum biomarkers in classical Hodgkin Lym-
phoma (cHL) reﬂect both tumor biology and burden in the
non-transplant setting.We sought to determine the prognostic
value of cHL serum biomarkers in predicting early relapse
following autologous stem cell transplantation (ASCT).
Table
Estimates and Relative Risks (RR) for 2-Year Relapse by Biomarker Strata Among All Patients
Biomarker Group All Patients PR Patients
N 2-Year Relapse
Estimate (95% CI)
P-value 2-Year RR for
Relapse (95% CI)
P-value N 2-Year Relapse
Estimate (95% CI)
P-value
IL-6 (pg/mL) < 2.15 18 11% (3-38%) 5 0%
 2.15 42 57% (42-72%) <0.01 7.11 (1.67-30.27) <0.01 19 59% (38-80%) 0.04
IL-10 (pg/mL) < 1.65 44 30% (19-47%) 17 30% (14-58%)
 1.65 16 75% (53-92%) <0.01 4.17 (1.88-9.29) <0.01 7 86% (54-99%) <0.01
sCD30(U/mL) < 8.65 39 32% (19-49%) 18 33% (17-60%)
 8.65 21 63% (43-82%) <0.01 2.88 (1.31-6.32) <0.01 6 100% 0.01
sIL-2R (U/mL) < 1276 52 37% (26-52%) 19 37% (20-63%)
1276 8 75% (44-96%) <0.01 3.38 (1.34-8.54) 0.01 5 80% (42-99%) 0.03
CCL17 (pg/mL) < 343.6 26 16% (6-36%) 8 13% (2-61%)
343.6 34 63% (47-79%) <0.01 6.10 (2.08-17.93) <0.01 16 63% (47-79%) 0.04
Galectin-1 (ng/mL) < 9.8 13 8% (1-43%) 3 0%
 9.8 47 52% (38-67%) <0.01 8.60 (1.16-63.54) 0.04 21 53% (34-75%) 0.14
CD68 (pg/mL) < 3.895 13 8% (1-43%) 5 0%
3.895 47 51% (38-67%) <0.01 8.53 (1.15-63.08) 0.04 19 59% (38-80%) 0.04
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S145Methods: Nine serum biomarkers (IL-6, IL-10, IL-13, sCD30,
sIL-2R, CCL17, Galectin-1, CD68 and CD163) selected for their
prognostic capacities in the upfront setting, were collected
pre-ASCT and measured in 61 patients undergoing trans-
plantation at the University of Minnesota or University of
Michigan. Using recursive partitioning methods, we calcu-
lated cutpoints for each biomarker to optimally separate
patients with early relapse (<2 years from ASCT) from those
with late relapse/complete remission (CR).
Results: The majority of patients (89%) were in CR (47%) or
partial remission (PR) (41%) at the time of transplant.
Twenty-six patients experienced early relapse following
ASCT, including 9 (31%) in CR and 12 (48%) in PR pre-ASCT.
Seven biomarkers identiﬁed patients with early relapse from
late relapse/CR (Table). By pre-ASCT disease status, no
biomarker distinguished early relapse among patients in CR
prior to transplantation. Six biomarkers identiﬁed early
relapse among patients in PR pre-ASCT.
Conclusions: Elevated serum biomarkers in cHL may identify
chemosensitive patients in pre-transplant PR at increased risk
for relapse. Identiﬁcation of these high-risk patients may offer
opportunities for intervention, such as alternative salvage
therapy pre-ASCT or post-ASCT maintenance therapy.168
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Introduction: Engraftment syndrome (ES) is a complication
of autologous hematopoietic progenitor cell transplantation
(AHPCT) characterized by fever, rash, pulmonary, liver, and/
or renal dysfunction. GM-CSF has been previously shown to
be associated with a higher risk of ES as compared to G-CSFafter AHPCT in heterogeneous patient cohort. We compared
the risk of ES with GM-CSF vs. G-CSF after AHPCT exclusively
in multiple myeloma (MM) patients who received the same
conditioning regimen.
Methods: We analyzed consecutive patients who received
melphalan 200 mg/m2 followed by an AHPCT for MM from
2008 to 2014. ES was diagnosed using a minor modiﬁcation
of the Maiolino criteria (MC) and Spitzer criteria (SC). ES
using MC was deﬁned as a noninfectious fever i 38C plus
rash or pulmonary inﬁltrates within 96 hours of neutrophil
recovery. ES using SC was deﬁned as the presence of 3 major
or 2 major plus 1 or more minor criteria within 96 hours of
neutrophil recovery (major criteria: noninfectious fever i
38C, rash, pulmonary inﬁltrates; minor criteria: liver/kidney
dysfunction, weight gain or encephalopathy). We analyzed
the incidence of ES using exact logistic regression, and time
to engraftment and hospital length of stay (LOS) using
Kaplan-Meier, logrank test and Cox proportional hazards
regression.
Results: A total of 111 patients were included (68 received
G-CSF and 43 received GM-CSF starting day +3 of AHPCT).
There was no signiﬁcant difference in patient age, gender
and race. Peripheral blood stem cell mobilization was ach-
ieved using a plerixafor-containing regimen in 45% of pa-
tients in the G-CSF group vs. 95% of patients in the GM-CSF
group (p¼0.001). A cyclophosphamide-containing regimen
was used for mobilization in 45% of patients in the G-CSF
group vs. 9% of patients in the GM-CSF group (p¼0.001). The
incidence of ES by MC and SC were 24% and 13%, respec-
tively. In unadjusted analysis, the GM-CSF group was
signiﬁcantly more likely to develop ES than the G-CSF group
using SC (28% vs. 3%; odds ratio, OR¼12.5; p¼0.001) and MC
(47% vs. 10%; OR¼7.42; p¼0.001). After adjusting for age,
gender, race and CD34+ cell dose, the GM-CSF group
remained at higher risk for ES than the G-CSF group
(OR¼10.4, p¼0.069 for SC; OR¼5.91, p¼0.029 for MC). The
GM-CSF group also had a signiﬁcantly longer time to
neutrophil engraftment than the G-CSF group by 1 day
(p¼0.001); the difference remained after multivariable
analysis (hazard ratio, HR¼0.22; 95% CI: 0.12 to 0.43;
p¼0.001). There was no signiﬁcant difference between the
two groups with respect to time to platelet engraftment
(p¼0.891). The median LOS of the G-CSF and GM-CSF group
was 15 and 16 days, respectively, although not statistically
signiﬁcant (p¼0.279).
